PerkinElmer
check quantity

TLectinSense 680 Fluorescent Imaging Agent

Near-infrared (NIR) fluorescent agent for in vivo imaging and other applications. 

For laboratory use only. This product is intended for animal research only and not for use in humans.

Part Number
List Price
Your Price
Quantity
NEV10060
631.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

Tumor neo-vasculature, characterized by the development of abnormal, leaky and tortuous blood vessels, represents a key target for cancer imaging and therapy. Among the various recognized tools for measuring microvessel density is tomato (Lycopersicon esculentum) lectin, a single polypeptide glycoprotein that binds to sugar-containing proteins present on the endothelium. 

TLectinSense™ 680 is a fluorescent in vivo endothelial cell imaging agent. TLectinSense 680 fluorescent agent is a near-infrared labeled macromolecule that targets the vasculature and enables imaging of blood vessels and angiogenesis. This agent in conjunction with PerkinElmer’s imaging instruments helps in assessing vascularity in vivo and in real time, without termination of mice, excision and processing of the tissue, thus improving the efficacy, early detection and monitoring of anti-angiogenic therapies.

Specifications

Fluorescent Agent Type Targeted
Optical Imaging Classification Fluorescence Imaging
Product Brand Name TLectinSense
Quantity in a Package Amount 1.0 Units
Shipping Condition Blue Ice
Therapeutic Area Angiogenesis, Oncology/Cancer
Unit Size 1 Vial (10 doses)
Wave Length 680 nm
Resources, Events & More
  • All

Brochure

TLectinSense™ 680 (Product Sheet)

The protein Tomato (L. esculentum) lectin is widely used for vascular,labeling, because the protein has high binding affinity for glycoprotein N-acetylglucosamines on the surface of vascular endothelial cells. The TLectinSense agent is a near-infrared fluorescent imaging probe designed and optimized for use in living animals. One of the gold standard,methods for vascular mapping ex vivo, is now enabled for use in vivo.

PDF 1 MB

Ebook

In Vivo Imaging Solutions eBook

Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.

PDF 4 MB

Flyer

Poster

Targeted in vivo imaging of tumor vasculature using a near infra-red labeled tomato lectin agent

Tumor neo-vasculature, characterized by the development of abnormal, leaky and tortuous blood vessels, represents a key target for cancer imaging and therapy. Among the various recognized tools for measuring microvessel density is tomato (Lycopersicon esculentum) lectin, a single polypeptide glycoprotein that binds to sugar-containing proteins present on the endothelium. The aim of this study was to develop a near infra-red tomato lectin imaging agent to non-invasively assess tumor vasculature in vivo. Conjugation of the near infra-red fluorophore VivoTag 680XL (epsilon=210,000/M/cm; abs/em max 665/688 nm) to tomato lectin was carried out by addition of the fluorophore in a DMSO solution to lectin in aqueous sodium bicarbonate. Yields of greater than 95% were achieved, based on absorbance, with a typical loading of 2 dyes per lectin. The resulting agent, TLectinSenseTM 680 (TL680), preferentially labeled primary human umbilical vein endothelial cells. Specificity of the binding was validated by control experiments using free dye and competitive blockade with excess unlabeled tomato lectin. In vivo, non-invasive, real-time imaging and quantification of tumor neo-vasculature was performed in two models: matrigel plugs containing bFGF, VEGF and heparin injected into the flank of SKH-1 mice and nude mice bearing Lewis Lung Carcinoma tumors. Using Fluorescence Molecular Tomography (FMT®) 6 hours after TL680 (4 nmoles) intravenous injection, tumor endothelium-associated fluorescence was detected in matrigel plugs and this...

PDF 1007 KB

Technical Note

TlectinSense 680 (Protocol)

Protocol for TlectinSense 680 Targeted Fluorescent In Vivo Imaging Agent

PDF 257 KB

White Paper

The Role of In Vivo Imaging in Drug Discovery and Development

The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.

PDF 748 KB